Our Services
Medical Information
Helpful Resources
Published on: 9/16/2026
Zetia (ezetimibe) can rarely cause liver enzyme elevations and muscle symptoms such as myalgia, myopathy, or in very rare cases rhabdomyolysis, though these risks are considerably lower than with statins when Zetia is taken alone. Risk rises when ezetimibe is combined with a statin or a fibrate, which is why doctors may order liver function tests and monitor for unexplained muscle pain, tenderness, weakness, dark urine, yellowing skin, or severe fatigue. Several factors influence individual risk, including dose, other medications, alcohol use, thyroid function, and pre-existing liver or kidney disease, so see below to understand the important details before drawing conclusions about your own symptoms. Muscle aches and fatigue while on cholesterol medication can also stem from causes entirely unrelated to the drug, and telling the difference matters for your treatment plan.
Because overlapping symptoms make self-diagnosis unreliable, a free, instant, online symptom check can help you organize what you are feeling, flag warning signs that need urgent attention, and clarify the questions worth raising with your doctor before your next refill.
Last reviewed for medical accuracy: 09/15/2025
Zetia (generic name: ezetimibe) is a cholesterol-lowering medication that works differently from statins. While statins block the liver enzyme responsible for making cholesterol, Zetia reduces the absorption of dietary cholesterol in your intestines. Because of this unique mechanism, side effects related to muscle and liver issues tend to differ from those seen with statins.
Below, we’ll break down what the research and product information tell us about:
Use clear, concise paragraphs and bullet points to guide you through the facts without unnecessary alarms—but do remember that serious or life-threatening symptoms always require prompt medical attention.
Zetia targets cholesterol at the source of entry into your body:
Many people take Zetia alone or in combination with a statin to achieve better cholesterol control. Its safety profile is generally favorable, especially compared with higher-dose statin therapy.
You may be more prone to liver enzyme changes if you:
Your risk may rise if you also:
Statins (e.g., atorvastatin, simvastatin, rosuvastatin) are highly effective at lowering LDL (“bad”) cholesterol but carry a higher risk of liver enzyme elevations and muscle problems. By contrast:
| Feature | Statins | Zetia (ezetimibe) |
|---|---|---|
| Liver enzyme changes | Up to 2–3% may have significant rises | <1% in monotherapy trials |
| Myalgias (muscle ache) | 5–10% in some studies | ~1–3%, mainly with statins |
| Serious rhabdomyolysis | Rare but documented | Very rare, almost always with statins |
| Mechanism | Inhibits liver cholesterol synthesis | Blocks intestinal absorption |
Key takeaway: Zetia alone has a much lower risk profile for muscle and liver toxicity than most statins. When used together, monitoring becomes more important.
Even though Zetia is generally well tolerated, stay aware of any new symptoms:
Signs of liver stress
Signs of muscle injury
If you notice any of these, stop the medication and contact your healthcare provider right away.
Baseline health check
Lifestyle measures
Follow-up care
Symptom checking tool
No online resource can replace personalized medical advice. Speak to your doctor if you experience:
Always report life-threatening or serious symptoms—such as intense abdominal pain, jaundice, or major muscle breakdown—immediately by calling emergency services.
Your physician or pharmacist can offer advice tailored to your health history and guide any necessary adjustments to your treatment plan. Remember, prompt attention to symptoms helps keep your therapy both safe and effective.
(References)
* Garcia-Valladares I, Espinoza LR. Ezetimibe-induced relapsing polymyositis. J Rheumatol. 2010 Feb;37(2):472. doi: 10.3899/jrheum.090660. PMID: 20147486.
* AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15. PMID: 22085343.
* Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):851-5. doi: 10.1517/17425255.2015.1027685. Epub 2015 Mar 18. PMID: 25786568.
* Fernandes V, Santos MJ, Pérez A. Statin-related myotoxicity. Endocrinol Nutr. 2016 May;63(5):239-49. doi: 10.1016/j.endonu.2016.01.001. Epub 2016 Mar 19. PMID: 27005745.
* Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608. PMID: 27039291.
* Tonstad S. [Statin intolerance]. Tidsskr Nor Laegeforen. 2017 Jan;137(1):36-38. doi: 10.4045/tidsskr.16.0646. Epub 2017 Jan 10. PMID: 28073228.
* Emerson A, Gonski P. Polypharmacy induced myositis. Intern Med J. 2020 Jan;50(1):128-130. doi: 10.1111/imj.14687. PMID: 31943612.
* Boutari C, Karagiannis A, Athyros VG. Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert Rev Cardiovasc Ther. 2021 Jul;19(7):575-580. doi: 10.1080/14779072.2021.1940959. Epub 2021 Jun 15. PMID: 34102931.
* Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. A Comprehensive Review of PCSK9 Inhibitors. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221100107. doi: 10.1177/10742484221100107. PMID: 35593194.
* Chen PS, Lin JL, Lin HW, Lin SH, Li YH. Risk of Hemorrhagic Stroke among Patients Treated with High-Intensity Statins versus Pitavastatin-Ezetimibe: A Population Based Study. Tohoku J Exp Med. 2024 Jun 28;263(2):105-113. doi: 10.1620/tjem.2024.J019. Epub 2024 Feb 22. PMID: 38382969.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.